What prices are disclosed for the BridgeBio (BBIO) CFO’s February 17, 2026 share sales?

The Form 4 lists sale prices of $74.7068 and $75.38 per share for the February 17 trades. It also notes a weighted average sale price range between $74.30 and $75.19 per share across the reported open-market transactions.

BridgeBio Pharma (BBIO) CFO sells 13,600 shares under trading plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma President and CFO Thomas Trimarchi reported a mix of tax withholding and planned share sales. On February 16, 2026, he disposed of 18,819 shares of common stock at $75.25 per share to cover taxes tied to the vesting of 37,503 RSU-based shares. On February 17, 2026, he sold a total of 13,600 shares of common stock in open-market transactions at prices of $74.7068 and $75.38 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 336,585 shares of BridgeBio common stock.

Insider Trade Summary

Net Seller: 13,600 shares ($1,016,147)

Net Sell 3 txns

Insider Trimarchi Thomas

Role President and CFO

Sold 13,600 shs ($1.02M)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,400	$74.7068	$1.00M
Sale	Common Stock	200	$75.38	$15K
Tax Withholding	Common Stock	18,819	$75.25	$1.42M

Holdings After Transaction: Common Stock — 336,785 shares (Direct)

Footnotes (1)

Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 37,503 shares of Common Stock underlying the Reporting Person's RSUs. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. Represents the weighted average sale price of the shares sold from $74.30 to $75.19 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

02/18/2026 - 06:36 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trimarchi Thomas

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/16/2026		F		18,819⁽¹⁾	D	$75.25	350,185	D
Common Stock	02/17/2026		S⁽²⁾		13,400	D	$74.7068⁽³⁾	336,785	D
Common Stock	02/17/2026		S⁽²⁾		200	D	$75.38	336,585	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 37,503 shares of Common Stock underlying the Reporting Person's RSUs.

2. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

3. Represents the weighted average sale price of the shares sold from $74.30 to $75.19 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did BridgeBio Pharma (BBIO) executive Thomas Trimarchi report in this Form 4?

Thomas Trimarchi reported tax-related share withholding and open-market sales of BridgeBio common stock. The filing shows both RSU-related tax dispositions and planned Rule 10b5-1 sales, along with his remaining direct share ownership after these transactions.

How many BridgeBio (BBIO) shares did the CFO sell in the open market?

The CFO sold a total of 13,600 BridgeBio common shares in open-market transactions. These trades occurred on February 17, 2026, at prices of $74.7068 and $75.38 per share as part of his disclosed Rule 10b5-1 trading plan.

What is the tax-withholding transaction disclosed for BridgeBio (BBIO) CFO Trimarchi?

The filing shows 18,819 BridgeBio common shares were withheld to satisfy Trimarchi’s tax obligations. This occurred on February 16, 2026, in connection with the vesting of 37,503 RSU-related shares, at a reported price of $75.25 per share.

Was the BridgeBio (BBIO) CFO’s stock sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the open-market sales were effected under a Rule 10b5-1 trading plan. That pre-arranged plan was adopted on March 31, 2025, and governed the February 17, 2026 transactions in BridgeBio common stock.

How many BridgeBio (BBIO) shares does CFO Thomas Trimarchi hold after these transactions?

After the reported transactions, Trimarchi directly held 336,585 shares of BridgeBio common stock. This post-transaction balance reflects the combination of his tax-withholding disposition and his Rule 10b5-1 open-market sales reported in the Form 4.